Antithrombotic prevention and therapy in coronary heart disease;Antithrombotische Pravention und Therapie bei koronarer Herzerkrankung

Internist

Volumn 38, Issue 7, 1997, Pages 658-666

  Bode, C ^a,b   Kohler, B ^a   Moser, M ^a   Zimmermann, R ^a   Strasser, R H ^a   Kubier W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Medizinische Klinik III   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; FIBRINOLYTIC AGENT;

BLOOD CLOT LYSIS; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; ORAL DRUG ADMINISTRATION; REVIEW; STENT; THROMBOCYTE AGGREGATION; BLOOD; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFECT;

ASPIRIN; CLINICAL TRIALS; CORONARY THROMBOSIS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION;

EID: 0030858336     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050077     Document Type: Review

References (63)

1. Steering Committee of the Physicians' Health Study Research Group (1989) Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl Med 321:129-135
2. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R (1988) Randomised trial of prophylacitc daily aspirin in Britisch mae doctors. B Med J 296:313-316
3. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R (1989) Aspirin and other atiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756
4. Cairns JA, Gent M, Sieger J, Finnie KJ, Frogatt GM, Holder DA, Jablowsky G, Kostuk WJ, Melendoz U, Myers MG (1985) Aspirin, sulfinpyrazone, or both in unstable angina. New Engl J Med 313:1369-1375
5. Théroux P, Ouim≤et H, Mccans J, Latour J-G, Joly P, Levy G, Pelletier E, Juneau, Stasiak J, deGuise P, Pelletier GB, Rinzler D,and Waters DD (1988) Aspirin, Heparin, or both to treat unstable angina. N Engl J Med 319:1105-1111
6. Lewis HD Jr., Davis JW, Archibald DG, Steinke WE, Smitheran TC, Doherty JE 3d, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effect of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396-403
7. Balsano F, Rizzon P, Violi F (1990) Antiplatelet treatment with ticlopidine in unstable angina. Circulation 82:17-26
8. The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336:827-830
9. Gurfinkel EP, Manos EJ, Mejail RI, Cerdá MA, Duronto EA, Garcia CN, Daroca AM, Mautner B (1995) Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 26:313-318
10. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. (1996) Lancet 347:561-568
11. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C (1994) Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Av'cute Coronary Syndromes Research Group.Circulation 89:81-88
12. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA (1994) Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 89:1557-1566
13. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global use of Strategies to Open Occluded coronary Arteries (GUSTO) lib investigators. N Engl J Med 335:775-782
14. Simoons ML, deBoer JM, Van deBrand MJBM, Can Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, Van der Weiken LR, deBono D, Rutsch W (1994) For the European Study Group: Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 89:596-603
15. Bode C, Gulba D, Huber K, Runge MS (1996) New aapproaches in plasminogen activator therapy Ann Hamatol 73 Suppl 1:51-57
16. Huber K, Runge M, Bode C, Gulba D (1996) Thrombolytic therapy in acute myocardial infarction - update 1996. Ann of Hematol 73 Suppl 1:529-538
17. Gulba DC, Bode C, Runge MS, Huber K (1996) Thrombolytic agents - an overview. Ann Hematol 73 Suppl 1:S9-S27
18. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br-Med-J 1988;296:320-331
19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B Med J 1994;308:81-106
20. Biagent C, Collins R (1993) ISIS-2: Four year mortality follow-up of 17.187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction (abstr.) Circulation 88:1-291
21. Patrono C (1994) Aspirin as antiplatelet drug. N Engl J Med 330:1287-1294
22. Roth GJ, Calverley DC (1994) Aspirin, platelets, and thrombosis: Theory and practice. Blood 83:885-898
23. Johannessen KA, Nordrehaug JE, von der Lippe G (1987) Left ventricular thrombi after short erm high dose anticoagulants in acute myocardial infarction. Eur Heart J 8:975-980
24. Smith P Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323:147-152
25. Anticoagulants in the secondary prevention of events in coronary thrombosis (ASPECT) Research Group: Effect of long term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503
26. Azar JA, Cannegieter SC, Deckers JW, Briet E, van Bergen P, Joncker JJ, Rosendal FR (1996) Optimal intensity of oral anticoagulant therapy after myocardial infarction J Am Coll Cardiol 27:1349-1355
27. Breddin K, Löw D, Lechner K, Oberia K, Wwalter E (1980) The German-Austrian Aspirin Trial: A comparison of acetylsalycylic acid, placebo and phenoprocoumon in secondary prevntion of myocardial infarction. Circulation 62:V62-V72
28. The Enquête de Prévention Secondaire de Ilnfarctus du Myocarde (EPSIM) Research Group: A controlled comparison of aspirin and oral antikoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307:701-708
29. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van Eenige MJ (1993) Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo controlled angiographic study. Results of the APRI-COT study. Circulation 87:1524-1530
30. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ (1994) Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol 74:657-661
31. The Persantine-Aspirin reinfarction Study Research Group (1980) Persantin and aspirin in coronary artery disease. Circulation 62:449-461
32. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ (1996) Differential dose response to oral Xemilofiban after antecedent intravenous abciximab. Circulation 94:906-910
33. Halperin JL and Petersen P (1992) Thrombosis in the cardiac chambers-Ventricular dysfunction and atrial fibrillation. In Thrombosis in cardiovascular disorders (Ed. Fuster V, Verstraete M), W.B. Suanders Co., Philadelphia 218
34. Kouvaras G, Chronopoulos G, Soufras G, Sofronas G, Solomos D, Bakirtzes A, Pissimisses E, Tzonou A, Cokkinos D (1990) The effects of long term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction. Am Heart J 119:73-78
35. Loh E, Sutton M, Wun Ch, Rouleau J, Flaker G, Gottlieb S, Lamas G, Moye L, Goldhaber S, Pfeffer M (1997) Ventricular Dysfunktion and the risk of stroke after myocardial infarction. N-Enl-J-Med 336:251-257
36. Hirsh J, Fuster V (1994) Guide to anticoagulant therapy, Part 2: Oral anticoagulants. Circulation 89:1469-1480
37. Theroux P, Lidon R-M (1993) Anticoagulants and their use in acute ischemic syndromes. In Textbook of Interventional Cardiology (Ed.Topol E), W.B. Saunders Co., Philadelphia 23-45
38. Ellis SG (1996) Percutaneous coronary intervention for stable angina. In: Cardiovascular therapeuticsed.: T.W.Smith
39. Ahmed W, Meckel C, Grines C (1995) Relation between ischemic complications and activated clotting times during coronary angioplasty: different profiles for heparin and hirulog. Circulation 92:1-608
40. Granger CB, Miller JM, Bovill EG (1995) Rebound and increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 91:1929-1935
41. Serruys PW, Herrmann J-PR, Simon R (1995) Comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N-Eng-J-Med 333:757-763
42. Bittl JA, Strony J, Brinker JA (1995) Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 333:764-769
43. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br-Med-J 308:159-168
44. The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet GPIIb-IIIa-receptor in high risk coronary angioplasty. N Engl J Med 330:956-961
45. Lincoff A; (1996) Evaluation of PTCA to improve Long-Term outcome by c7E3 GP IIb-IIIa receptor blockade (EPILOG) results of the interim analysis. J Am Coll Cardiol 27 (supplA)
46. Van de Werf F (1996) More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur J Med 17:325-326
47. Horrigan MCG, Tcheng JE, Califf RM (1996) Maximal benefit of integrelin platelet GP IIb-IIIa blockade 6-12 hours after therapy: results of the IMPAQ II Trial abstract. J Am Coll Cardiol 27:55A
48. Egbertson MS, Chang CT, Duggen ME, Gould RJ, Halsczenko W, Hartman GD, Laswell WL, Lynch JJ jun., Lynch RJ, Manno PD (1994) Non-Peptide fibrinogen receptor antagonisten. II Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 37:2537-2551
49. King SB III (1996) Administration of tirofiban (MK 0383) will reduce the incidence of adverse cardiac outcome following PTCA/PC A (RESTORE) abstract. J Am Coll Cardiol 27 (supplA)
50. More R, Chauhan A (1997) Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet 349:146-147
51. Goldman S, Copeland J, Moritz T (1988) Improvement in early saphenous ven graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a veterans administration cooperative study. Circulation 77:1324-1332
52. Campeau L, Enjylbert M, Lesperance J, Vaislic C, Grondin CM, Bourassa MG (1983) Athetosderosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 68(suppl II):II-1-7
53. Loop FD, Lytle BW, Cosgrove DM (1986) Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 314:1-6
54. Sanz G, Pajaron A, Alegria E, et al (1990) Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamol Circulation 82:765-773
55. Chesebro JH, Clements I, Fuster V (1982) A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamol and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307:73-78
56. Lorenz RL, Schacky CV, Weber M (1984) Improved coronary artery bypass patency by low-dose aspirin (100 mg/d). Lancet 1:1261-1264
57. Pantely GA, Goodnight SH Jr, Rahimtoola SH (1979) Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass. N Engl J Med 301:962-966
58. Chesebro JH, Lam JY, Fuster V (1986) The pathogenesis and prevention of aortocoronary vein bypass graft occlusion and restenosis after arterial angioplasty: role of vascular injury and platelet thrombus deposition. J Am Coll Cardiol 8(6 Suppl B)56B-66B
59. Pfisterer M, Jockers G, Regenass (1989) Trial of low-dose aspirin plus dipyridamol versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 2(8653):1-7
60. Henderson WG, Goldman S, Copeland JG, Moritz TE, Harker LA (1989) Antiplatelet or anticoagulant therapy after coronary artery bypass surgery. A meta analysis of clinical trials. Ann Int Med 111:743-750
61. Antipatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categorie of patients. B Med J 308:81-106
62. Sinzinger H, Virgolini I, Peskar BA (1989) Response of thromboxane B2, maleonyldialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) in healthy volunteers. Thromb Res 53:261-269
63. Witt I (1994) 1st die "International Normalized Ratio (INR)" in der klinischen Praxis unentbehrlich? Dtsch med Wschr 119:1529-1531